What is the appropriate ondansetron (Zofran) dose for a 4‑year‑old male weighing 25 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ondansetron Dosing for a 4-Year-Old, 25 kg Male

For this 4-year-old child weighing 25 kg, administer ondansetron 0.15 mg/kg per dose, which equals 3.75 mg (rounded to 4 mg in clinical practice), with a maximum single dose of 16 mg. 1

Weight-Based Dosing Calculation

  • The standard pediatric dose is 0.15 mg/kg per dose for children ≥6 months of age 1, 2
  • For a 25 kg child: 25 kg × 0.15 mg/kg = 3.75 mg per dose 1
  • The maximum single dose is capped at 16 mg regardless of weight 1, 2
  • This child is well below the maximum dose threshold 1

Route of Administration

Intravenous (IV) Route

  • IV is preferred for severe symptoms (e.g., severe vomiting with dehydration, hypotension, or extreme lethargy) 1
  • Administer 0.15 mg/kg (3.75 mg for this patient) IV 1

Intramuscular (IM) Route

  • IM may be used when IV access is unavailable or delayed 1
  • Same dose applies: 0.15 mg/kg (3.75 mg) IM 1

Oral Route

  • Oral ondansetron at 0.1-0.15 mg/kg has demonstrated efficacy in pediatric patients 2, 3
  • The injectable formulation can be given orally if needed 3

Dosing Frequency

  • The dose can be repeated every 8 hours as clinically indicated 2, 4
  • For chemotherapy-induced emesis, the typical regimen is three doses: 30 minutes before chemotherapy, then at 4 and 8 hours afterward 4
  • In acute care settings without hepatic impairment, dosing can be repeated as needed 1

Important Safety Considerations

Cardiac Precautions

  • Exercise special caution in children with underlying heart disease due to potential QT interval prolongation 1
  • Monitor for arrhythmias in at-risk patients 1

Age Eligibility

  • This 4-year-old patient meets the age requirement (≥6 months) for ondansetron use 1

Common Adverse Effects

  • Mild to moderate headache, constipation, and diarrhea are most frequently reported 2
  • In postoperative settings, wound problems, anxiety, drowsiness, and pyrexia may occur 2
  • Serious adverse events are rare, with severe reactions occurring in <1% of pediatric patients 5

Clinical Context-Specific Dosing

The 0.15 mg/kg dose (3.75 mg for this 25 kg child) is appropriate across multiple clinical scenarios:

  • Chemotherapy-induced nausea/vomiting: 0.15 mg/kg IV/IM 1, 2
  • Postoperative nausea/vomiting: 0.15 mg/kg IV (though doses as low as 0.05 mg/kg have shown efficacy) 6
  • Food protein-induced enterocolitis syndrome (FPIES): 0.15 mg/kg IV for severe symptoms or IM for moderate symptoms 1

Practical Dosing Note

While the calculated dose is 3.75 mg, rounding to 4 mg is clinically appropriate and safe given the wide therapeutic window and the fact that doses up to 0.45 mg/kg have been used in pediatric patients without significant adverse effects 3.

References

Guideline

Ondansetron Dosing Guidelines for Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Ondansetron: a novel antiemetic agent.

Southern medical journal, 1993

Research

Safety of ondansetron loading doses in children with cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008

Research

Ondansetron dose response curve in high-risk pediatric patients.

Journal of clinical anesthesia, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.